Online citations, reference lists, and bibliographies.
← Back to Search

Single-agent Treatment With Pegylated Liposomal Doxorubicin For Metastatic Breast Cancer

M. O'Brien
Published 2008 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Anthracyclines and taxanes are among the most active substances used in the treatment of metastatic breast cancer (MBC). Their frequent use in the adjuvant setting and in cumulative toxicities including cardiotoxicity, however, often limit their use in MBC. The trend towards the use of adjuvant trastuzumab-containing regimens, which can also produce cardiotoxicity, adds further support to the need for effective agents with improved tolerability in the metastatic setting. Pegylated liposomal doxorubicin (PLD) can be an effective alternative to conventional anthracyclines for certain women with MBC. In phase III clinical trials, PLD was as effective as doxorubicin and produced significantly less cardiotoxicity in women with MBC. The incidences of myelotoxicity, nausea/vomiting, and alopecia were also lower with PLD, whereas hand–foot syndrome and stomatitis occurred more frequently. Phase II and III trials conducted in women with MBC support the use of PLD monotherapy in patients relapsing after adjuvant anthracycline-containing therapy, in heavily pretreated patients with taxane-refractory disease, in patients with cardiovascular risk factors (e.g. hypertension and mediastinal irradiation), in elderly patients, and in patients for whom specific acute doxorubicin toxicities, such as alopecia, are particularly worrying.
This paper references
Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes
Z. Symon (1999)
The 27th annual San Antonio breast cancer symposium
R. Short (2005)
Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies
A Gabizon (2003)
Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial.
M. Ranson (1997)
Doxorubicin-induced cardiomyopathy.
F. Otero (2000)
Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer
E. Rivera (2001)
for the 303 Study Group. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer
S Chan (1999)
A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).
R. Coleman (2006)
HER2 and responsiveness of breast cancer to adjuvant chemotherapy.
K. Pritchard (2006)
Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin
B. Conley (2004)
Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
S. Chia (2006)
Cardiac dysfunction in the trastuzumab clinical trials experience.
A. Seidman (2002)
Trastuzumab sensitivity of breast cancer with co-amplification of HER2 and cMYC suggests pro-apoptotic function of dysregulated cMYC in vivo
C Kim (2005)
Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.
G. Batist (2001)
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.
Alan M. Keller (2004)
Innovations in anthracycline therapy: overview
JT Thigpen (2005)
Risk factors for doxorubicin-induced congestive heart failure.
D. V. Von Hoff (1979)
Study Group. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer
S Chan (1999)
Congestive heart failure in patients treated with doxorubicin
S. Swain (2003)
Developing drugs to decrease the toxicity of chemotherapy.
G. Williams (2001)
Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.
V. Pai (2000)
Anthracycline-induced cardiotoxicity and its relevance in cancer treatment
C Praga (1991)
Liposome-based drug delivery in breast cancer treatment
J. Park (2002)
The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial
S. Al-Batran (2006)
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
M. O'Brien (2004)
A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer
R E Coleman
National Comprehensive Cancer Network website . Clinical practice guidelines in oncology : breast cancer v . 2 . 2006
MR Ranson
The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer.
N. Robert (2004)
Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review).
M. Orditura (2004)
Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
S. Chan (1999)
Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma
O. Lyass (2000)
Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies.
D. Vail (2004)
Clinical practice guidelines in oncology: breast cancer v
Phase II Study of Single-Agent Pegylated Liposomal Doxorubicin HCl (PLD) in Metastatic Breast Cancer After First-Line Treatment Failure
B. Mlineritsch (2004)
Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer.
M. Ryberg (1998)
Phase II randomized trial of pegylated liposomal doxorubicin versus weekly docetaxel with subsequent crossover as first-line chemotherapy for metastatic breast cancer
DA Yardley (2004)
Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer.
P. Rose (2005)
Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity
M Orditura
Advantages of liposomal delivery systems for anthracyclines.
T. Allen (2004)
Prolongation of TTP by maintenance therapy with PLD in a multicenter phase III randomized trial following standard chemotherapy for MBC: GEICAM 2001-01 study
E. Alba (2007)
Reduced Incidence of Severe Palmar-Plantar Erythrodysesthesia and Mucositis in a Prospective Multicenter Phase II Trial with Pegylated Liposomal Doxorubicin at 40 mg/m2 Every 4 Weeks in Previously Treated Patients with Metastatic Breast Cancer
S. Al-Batran (2006)

This paper is referenced by
The most prevalent side effects of pegylated liposomal doxorubicin monotherapy in women with metastatic breast cancer: a systematic review of clinical trials
L. Ansari (2017)
A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer
J. Huober (2009)
Overcoming Taxane and Anthracycline Resistance
A. Zelnak (2010)
5-Fluorouracil derivatives: a patent review
P. Álvarez (2012)
Pegylated Liposomal Doxorubicin
S. Duggan (2012)
A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer
Z. Vujasković (2010)
Characterisation of TRAIL Receptor Signalling To Apoptosis in Pre-clinical Models of Breast Cancer
Shambhavi Naik (2011)
Optimization of Plasma Treatment, Manipulative Variables and Coating Composition for the Controlled Filling and Coating of a Microstructured Reservoir Stent
M. Mekki (2009)
Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study
V. Adamo (2008)
Metronomic Chemotherapy in Breast Cancers
E. Munzone (2014)
Delayed photolysis of liposomes: a strategy for the precision timing of bolus drug release using ex-vivo photochemical sensitization
Raymond T. Kozikowski (2012)
Enhancement of CD4+ T-cell help reverses the doxorubicin-induced suppression of antigen-specific immune responses in vaccinated mice
D. Kim (2008)
Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long‐term results from a single institution experience
P. Martin-Romano (2018)
PGSE-NMR and SANS studies of the interaction of model polymer therapeutics with mucin.
P. Griffiths (2010)
Nanoparticle therapeutics: an emerging treatment modality for cancer
M. Davis (2008)
Clinical overview of metronomic chemotherapy in breast cancer
E. Munzone (2015)
Extracorporeal apheresis system – A nanoparticle drugs’ elimination method to enhance the benefit of cytostatic therapy in cancer patients
S. Filip (2016)
Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: a mono-institutional case-series report.
E. Munzone (2010)
This information is current as Encephalomyelitis of Experimental Autoimmune TreatmentAlters Their Mode of Action in the Liposomal Encapsulation of Glucocorticoids
Fred Lühder (2011)
Options for the treatment of patients with taxane-refractory metastatic breast cancer.
B. Overmoyer (2008)
Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary.
E. Chuang (2010)
Liposomal Encapsulation of Glucocorticoids Alters Their Mode of Action in the Treatment of Experimental Autoimmune Encephalomyelitis
N. Schweingruber (2011)
The role of milk thistle extract in breast carcinoma cell line (MCF-7) apoptosis with doxorubicin.
Hussein Rastegar (2013)
Récidive homolatérale des cancers du sein : quels traitements adjuvants systémiques ?
H. Curé (2010)
Predictors of new-onset heart failure and overall survival in metastatic breast cancer patients treated with liposomal doxorubicin
S. Szmit (2020)
Alteration of matrix metalloproteinases in selective left ventricular adriamycin-induced cardiomyopathy in the pig.
A. Goetzenich (2009)
Pegylated Liposomal Doxorubicin (Caelyx®) and Oral Vinorelbine in First-Line Metastatic Breast Cancer Patients Previously Treated with Anthracyclines
L. Livi (2011)
Liposomal nanomedicines as anticancer therapeutics: beyond targeting tumor cells.
R. Schiffelers (2008)
Real-time electrochemical monitoring of drug release from therapeutic nanoparticles.
L. Mora (2009)
Uptake and intracellular trafficking of nanoparticles for potential medical use
Lettiero (2011)
Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study
K. Rau (2015)
Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.
C. Hantel (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar